CIK 0001651308
- Large accelerated filer
BeOne Medicines Ltd.
Sign in to watch- Ticker
- BEIGF
- Exchange
- Nasdaq, OTC
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- Operating
- EIN
- 981209416
- Phone
- +41 616851900
- Business address
- C/O BEONE MEDICINES I GMBH, AESCHENGRABEN 27, 21ST FLOOR, BASEL, Switzerland, 4051
- Former names
- BeiGene, Ltd.
Securities
- ONC American Depositary Shares Nasdaq
- BEIGF Common stock OTC
- 4 Gift Director gave 67,444 shares (gift)
- 4 Open-market sale Director sold 67,635 shares at an average $226.03 ($15,287,339)
- 4 Open-market sale Chief Financial Officer sold 343 shares at $240.21 ($82,392)
- 4 Open-market sale Director sold 5,000 shares at an average $260.52 ($1,302,585)
- 4 Open-market sale Chief Executive Officer sold 20,391 shares at an average $248.51 ($5,067,449)
- 4 Open-market sale Director sold 5,000 shares at an average $251.36 ($1,256,799)
- 4 Open-market sale Chief Executive Officer sold 9,609 shares at an average $224.43 ($2,156,572)
- 4 Open-market sale Director sold 3,013 shares at an average $211.33 ($636,723)
- 4 Gift Director gave 52,000 shares (gift)
- 4 Open-market sale Director sold 1,987 shares at $210.14 ($417,541)
- 4 Open-market sale Chief Executive Officer sold 29,928 shares at an average $206.84 ($6,190,334)
- 4 Open-market sale Chief Executive Officer sold 50,000 shares at an average $152.13 ($7,606,556)
- 4 Gift Director gave 33,410 shares (gift)
- 4 Other disposition Director disposed of 7,800 shares (other)
- 4 Other acquisition 10% owner acquired 7,800 shares (other)
- 4 Open-market sale Director sold 16,060 shares at an average $196.65 ($3,158,121)
- 4/A Open-market sale Chief Financial Officer sold 317 shares at $158.50 ($50,245)
- 4 Open-market sale Chief Financial Officer sold 295 shares at $158.50 ($46,758)
- 4 Open-market sale Global Head of R&D sold 458 shares at $177.32 ($81,215)
- 4 Grant or award Chief Executive Officer acquired 334,009 shares (grant or award)
Page 12 of 29 · 580 filings